Skip to main content

Table 4 Prognosis in 2 years after liver transplantation

From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

 

MSC (N = 11)

Rituximab (N = 11)

P value

Survival rate no. (%)

9 (81.8%)

8 (72.7%)

1.000

Graft survival rate no. (%)

9 (81.8%)

8 (72.7%)

1.000

Acute rejection no. (%)

1 (9.1%)

3 (27.3%)

0.586

Biliary complications no. (%)

0 (0%)

5 (45.5%)

0.035a

Ischemia type biliary lesion no. (%)

0 (0%)

4 (36.4%)

0.090

Bile duct anastomotic stenosis no. (%)

0 (0%)

3 (27.3%)

0.214

Bile leakage no. (%)

0 (0%)

1 (9.1%)

1.000

Septic shock no. (%)

1 (9.1%)

9 (81.8%)

0.002b

Pulmonary infection no. (%)

0 (0%)

8 (72.7%)

0.001b

Biliary infection no. (%)

0 (0%)

1 (9.1%)

1.000

Splenic abscess no. (%)

1 (9.1%)

0 (0%)

1.000

Arteriostenosis no. (%)

1 (8.3%)

3 (27.3%)

0.586

De novo tumor no. (%)

0 (0%)

1 (9.1%)

1.000

  1. aP < 0.05, bP < 0.01
  2. Abbreviations: MSC mesenchymal stem cell